A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.
about
Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasionCloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysisAn alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activatorA novel, specific pro-urokinase complex on monocyte-like cells, detected by transglutaminase-catalyzed cross-linkingDirect binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activityThe receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexesUrokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applicationsVEGF-initiated angiogenesis and the uPA/uPAR systemStructure-based Engineering of Species Selectivity in the Interaction between Urokinase and Its Receptor: IMPLICATION FOR PRECLINICAL CANCER THERAPYThe urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motilitySuppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascadeThe urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodelingPlasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular formsAccessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitorProcessing of complex between urokinase and its type-2 inhibitor on the cell surfaceExtracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancerDifferential roles of uPAR in peritoneal ovarian carcinomatosisBinding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility.Modulation of cellular migration and survival by c-Myc through the downregulation of urokinase (uPA) and uPA receptorElevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group.Urokinase-type plasminogen activator supports liver repair independent of its cellular receptoruPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer.Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis kneesDecrease in plasminogen activator correlates with synapse elimination during neonatal development of mouse skeletal muscle.Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.Plasminogen activator inhibitor-1 and the kidney.Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future ProspectsThe role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis.The plasminogen activator/plasmin systemDifferential protease expression by cutaneous squamous and basal cell carcinomas.Urokinase has direct catalytic activity against fibrinogen and renders it less clottable by thrombinFunctional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.Characterization and function of human Ly-6/uPAR molecules.Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis.Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator.Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.A deficiency of uPAR alters endothelial angiogenic function and cell morphology.Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpressionUrokinase and its receptors in chronic kidney disease.
P2860
Q22000757-D8172DBD-F3F6-469A-9E45-B0C8708E1325Q24299135-2FB4637D-C1AC-47C5-8819-3C05136F8777Q24316221-A33CFD41-8025-4FB6-914C-EE291C28FD81Q24318514-6CB23BBC-1018-4E55-B045-AFF357D959C7Q24633333-576EA114-5DF7-4F81-A14A-E06DFBA9920EQ24678932-4512854F-50B3-4E1A-B2E9-6A200BAF37CDQ26865306-B1372409-7CE6-48C6-B47D-EB9FF4453CA7Q27025897-EC88CC58-222F-480E-8DE0-24C44092FAAFQ27659603-4C0DB4EF-8693-467B-907D-B33FDFBEAC25Q28212178-BA7ADF24-D4B0-4BB7-9C97-68F63518051CQ28218095-D6E452C5-757F-40FE-A7AB-DFD9188175B4Q28257803-7EBAE460-BCA1-4126-B32C-08BB6EE79607Q28285553-F8B59AA7-1402-4BB1-8277-0EA9D11D7AB3Q28647054-0454AADC-444F-4F11-B9EE-8BB70DB10222Q29306421-CAFCD4F7-4F7D-46EB-8D34-1720300F63D2Q30164226-BE8A7851-7E7B-43F9-A45C-E077DCF79AFCQ30426956-8B67B695-FD71-4CEE-BA3A-83A9803F9879Q30471919-7FDB1348-6058-4756-A86D-DBC8D5B4DEDCQ30493647-AF659D0E-037F-4473-956F-0D3806CEA27FQ31038443-C3A4A5C0-93AE-4537-A33D-109BF445D4F7Q33264968-6E8ED109-2279-4F2D-869F-A6066250A393Q33376876-504FBE68-5C81-48F0-8533-4095C3E2DF4BQ33578860-A19175C4-3D80-4872-88AE-C870C0235552Q33830088-81E95142-FE86-487A-95FD-87526D8B3CF3Q33886514-E29EAFAD-5E1D-4BC8-9899-B56ED9A105C7Q33895912-BD747CD4-F68F-4DC0-AAE8-599B9D6749CAQ33960082-B3B49697-4EEC-49B5-AA3A-0F695B306F94Q34095769-D098DA6F-0247-47A1-B2AC-4C19AEC46202Q34165118-440D5188-EBB8-4648-8EEC-9F1B73996A4AQ34202297-5536C412-0D18-4606-B0CA-7B77E45C4F08Q34202408-BEC6831E-2A00-42D4-B889-BE5BD08AEFB3Q34256090-13FD5E1E-4079-474C-AC33-B8DCFD917FFAQ34290829-A70A686C-D3B1-4DE7-B8B7-6C191715ADF1Q34314038-5C6FE518-2B5F-49E7-BB67-16C6AF2654BEQ34489359-8F8C2550-1B2E-43C0-AEB3-4D3412D9FA47Q34606581-3CD81D9E-2CF9-45EE-A893-40ACE9495FE9Q34777224-2AE9336E-82A4-43A4-BC43-D1081FF5B11AQ35019176-829755ED-3E0E-4583-85F9-B8BD8A4F67CBQ35098346-712D727A-17A0-4D1B-A74B-D895BA7504F8Q35124141-F71AFA4E-0CAD-4CF7-BE3B-5C832C9FFBA2
P2860
A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh
1985年學術文章
@zh-hant
name
A cellular binding site for th ...... sminogen activator, urokinase.
@ast
A cellular binding site for th ...... sminogen activator, urokinase.
@en
type
label
A cellular binding site for th ...... sminogen activator, urokinase.
@ast
A cellular binding site for th ...... sminogen activator, urokinase.
@en
prefLabel
A cellular binding site for th ...... sminogen activator, urokinase.
@ast
A cellular binding site for th ...... sminogen activator, urokinase.
@en
P2093
P2860
P356
P1476
A cellular binding site for th ...... sminogen activator, urokinase.
@en
P2093
P2860
P356
10.1083/JCB.100.1.86
P407
P577
1985-01-01T00:00:00Z